Latest & greatest articles for ace inhibitors

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on ace inhibitors or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on ace inhibitors and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

ACE inhibitors

Angiotensin converting enzyme inhibitors (ACE) are principally used to reduce blood pressure. ACE inhibitors work by reducing the activity of the renin-angiotensin-aldosterone system. They have been used in a variety of conditions, including hypertension, acute myocardial infarctions, left ventricular systolic dysfunction and diabetic nephropathy

Ace inhibitors can be used alone to treat hypertension, or they can be used in combination with other drugs such as diuretics. Case studies and clinical trials on the medicine show that it can be used to prevent stroke or heart attacks. Common side effects of the drug including hypotension, dry cough, hyperkalaemia, headache, dizziness, fatigue, nausea, renal impairment and swelling in the lips and tongue.

ACE Inhibitors are widely used and feature extensively in the literature including clinical guidelines, systematic reviews, randomised controlled trials, case studies etc. These can easily be found via a search of the Trip Database. Medical research is vital to the development of new treatments and therapies for hypertension.

Top results for ace inhibitors

1. ACE inhibitors and ARBs: One or the other -- not both -- for high-risk patients

ACE inhibitors and ARBs: One or the other -- not both -- for high-risk patients ACE inhibitors and ARBs: One or the other -- not both -- for high-risk patients Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics ACE inhibitors and ARBs: One or the other -- not both -- for high-risk patients View/ Open Date 2009-01 Format (...) Metadata Abstract Avoid prescribing an angiotensin-converting enzyme (ACE) inhibitor and an angiotensin receptor blocker (ARB) for patients at high risk of vascular events or renal dysfunction. The combination does not reduce poor outcomes, and leads to more adverse drug-related events than an ACE inhibitor or ARB alone. Strength of recommendation: B: 1 large, high-quality randomized controlled trial (RCT). URI Part of Citation Journal of Family Practice, 58(1) 2009: 24+. Collections hosted by hosted by

PURLS2018

2. ACE inhibitors

ACE inhibitors Top results for ace inhibitors - Trip Database or use your Google+ account Turning Research Into Practice My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box (...) and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for ace inhibitors The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical

Trip Latest and Greatest2018

3. Do ACE inhibitors or ARBs help prevent kidney disease in patients with diabetes and normal BP?

Do ACE inhibitors or ARBs help prevent kidney disease in patients with diabetes and normal BP? Do ACE inhibitors or ARBs help prevent kidney disease in patients with diabetes and normal BP? Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics Do ACE inhibitors or ARBs help prevent kidney disease in patients with diabetes (...) and normal BP? View/ Open Date 2017-04 Format Metadata Abstract Q: Do ACE inhibitors or ARBs help prevent kidney disease in patients with diabetes and normal BP? Evidence-based answer: Yes for angiotensin-converting enzyme (ACE) inhibitors, no for angiotensin receptor blockers (ARBs). In normotensive patients with type 1 and type 2 diabetes, ACE inhibitor therapy reduces the risk of developing diabetic kidney disease, defined as new-onset microalbuminuria or macroalbuminuria, by 18% (strength

Clinical Inquiries2018

4. ACE Inhibitors and Statins in Adolescents with Type 1 Diabetes.

ACE Inhibitors and Statins in Adolescents with Type 1 Diabetes. BACKGROUND: Among adolescents with type 1 diabetes, rapid increases in albumin excretion during puberty precede the development of microalbuminuria and macroalbuminuria, long-term risk factors for renal and cardiovascular disease. We hypothesized that adolescents with high levels of albumin excretion might benefit from angiotensin-converting-enzyme (ACE) inhibitors and statins, drugs that have not been fully evaluated (...) in adolescents. METHODS: We screened 4407 adolescents with type 1 diabetes between the ages of 10 and 16 years of age and identified 1287 with values in the upper third of the albumin-to-creatinine ratios; 443 were randomly assigned in a placebo-controlled trial of an ACE inhibitor and a statin with the use of a 2-by-2 factorial design minimizing differences in baseline characteristics such as age, sex, and duration of diabetes. The primary outcome for both interventions was the change in albumin excretion

NEJM2017

5. Hypertension and diabetes: if chlortalidone is unavailable, an ACE inhibitor should be the drug of choice

Hypertension and diabetes: if chlortalidone is unavailable, an ACE inhibitor should be the drug of choice Prescrire IN ENGLISH - Spotlight ''Hypertension and diabetes: if chlortalidone is unavailable, an ACE inhibitor should be the drug of choice'', 1 June 2017 {1} {1} {1} | | > > > Hypertension and diabetes: if chlortalidone is unavailable, an ACE inhibitor should be the drug of choice Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |    (...) |   |   |   |   |   |   |  Spotlight Hypertension and diabetes: if chlortalidone is unavailable, an ACE inhibitor should be the drug of choice Hypertension treatment in diabetes patients aims to reduce the risk of complications: cardiovascular events, end-stage renal failure, deterioration of eyesight. Patients with diabetes are exposed to arterial damage, including coronary artery disease and stroke, and damage to the blood capillaries

Prescrire2017

8. Cohort study: ACE inhibitors in African Americans with hypertension associated with worse outcomes as compared to other antihypertensives

Cohort study: ACE inhibitors in African Americans with hypertension associated with worse outcomes as compared to other antihypertensives ACE inhibitors in African Americans with hypertension associated with worse outcomes as compared to other antihypertensives | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username (...) * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here ACE inhibitors in African Americans with hypertension associated with worse outcomes as compared to other antihypertensives Article Text Prognosis Cohort study ACE inhibitors in African Americans with hypertension associated with worse outcomes

Evidence-Based Medicine (Requires free registration)2016

9. Treatment of Angiotensin Converting Enzyme (ACE) Inhibitor-Induced Angioedema: Guidelines

Treatment of Angiotensin Converting Enzyme (ACE) Inhibitor-Induced Angioedema: Guidelines Treatment of Angiotensin Converting Enzyme (ACE) Inhibitor-Induced Angioedema: Guidelines | CADTH.ca Find the information you need Treatment of Angiotensin Converting Enzyme (ACE) Inhibitor-Induced Angioedema: Guidelines Treatment of Angiotensin Converting Enzyme (ACE) Inhibitor-Induced Angioedema: Guidelines Published on: November 26, 2015 Project Number: RB0938-000 Product Line: Research Type: Drug (...) Report Type: Summary of Abstracts Result type: Report Question What are the evidence-based guidelines regarding the treatment of patients with angiotensin-converting enzyme inhibitor-induced angioedema? Key Message Four evidence-based guidelines were identified regarding the treatment of patients with angiotensin-converting enzyme inhibitor-induced angioedema. Tags angioedema, angioneurotic edema, quincke's edema, angio-oedema, angiooedema Files Rapid Response Summary of Abstracts Published

Canadian Agency for Drugs and Technologies in Health - Rapid Review2015

11. Angiotensin-converting enzyme (ACE) inhibitors for proteinuria and microalbuminuria in people with sickle cell disease.

Angiotensin-converting enzyme (ACE) inhibitors for proteinuria and microalbuminuria in people with sickle cell disease. BACKGROUND: Sickle cell disease is a group of disorders characterized by deformation of erythrocytes. Renal damage is a frequent complication in sickle cell disease as a result of long-standing anemia and disturbed circulation through the renal medullary capillaries. Due to the improvement in life expectancy of people with sickle cell disease, there has been a corresponding (...) significant increase in the incidence of renal complications. Microalbuminuria and proteinuria are noted to be a strong predictor of subsequent renal failure. There is extensive experience and evidence with angiotensin-converting enzyme (ACE) inhibitors over many years in a variety of clinical situations for patients who do not have sickle cell disease, but their effect in people with this disease is unknown. It is common practice to administer ACE inhibitors for sickle nephropathy due

Cochrane2015

12. Icatibant in ACE-Inhibitor-Induced Angioedema.

Icatibant in ACE-Inhibitor-Induced Angioedema. Icatibant in ACE-inhibitor-induced angioedema. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 25946291 Format MeSH and Other Data E-mail Subject Additional text E (...) -mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2015 May 7;372(19):1867-8. doi: 10.1056/NEJMc1503671. Icatibant in ACE-inhibitor-induced angioedema. , , . Comment on [N Engl J Med. 2015] [N Engl J Med. 2015] [N Engl J Med. 2015] [N Engl J Med. 2015] PMID: 25946291 DOI: [Indexed for MEDLINE] Free full text Publication types MeSH terms Substances Full Text Sources Miscellaneous PubMed

NEJM2015

13. Icatibant in ACE-Inhibitor-Induced Angioedema.

Icatibant in ACE-Inhibitor-Induced Angioedema. Icatibant in ACE-inhibitor-induced angioedema. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 25946292 Format MeSH and Other Data E-mail Subject Additional text E (...) -mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2015 May 7;372(19):1866. doi: 10.1056/NEJMc1503671#SA1. Icatibant in ACE-inhibitor-induced angioedema. . Comment in [N Engl J Med. 2015] Comment on [N Engl J Med. 2015] PMID: 25946292 DOI: [Indexed for MEDLINE] Publication types MeSH terms Substances Full Text Sources Miscellaneous PubMed Commons 0 comments How to cite this comment

NEJM2015 Full Text: Link to full Text with Trip Pro

14. Icatibant in ACE-Inhibitor-Induced Angioedema.

Icatibant in ACE-Inhibitor-Induced Angioedema. Icatibant in ACE-inhibitor-induced angioedema. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 25946293 Format MeSH and Other Data E-mail Subject Additional text E (...) -mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2015 May 7;372(19):1866. doi: 10.1056/NEJMc1503671#SA2. Icatibant in ACE-inhibitor-induced angioedema. , . Comment in [N Engl J Med. 2015] Comment on [N Engl J Med. 2015] PMID: 25946293 DOI: [Indexed for MEDLINE] Publication types MeSH terms Substances Full Text Sources Miscellaneous PubMed Commons 0 comments How to cite this comment

NEJM2015 Full Text: Link to full Text with Trip Pro

15. Icatibant in ACE-Inhibitor-Induced Angioedema.

Icatibant in ACE-Inhibitor-Induced Angioedema. Icatibant in ACE-inhibitor-induced angioedema. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 25946294 Format MeSH and Other Data E-mail Subject Additional text E (...) -mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2015 May 7;372(19):1867. doi: 10.1056/NEJMc1503671#SA3. Icatibant in ACE-inhibitor-induced angioedema. , , . Comment in [N Engl J Med. 2015] Comment on [N Engl J Med. 2015] PMID: 25946294 DOI: [Indexed for MEDLINE] Publication types MeSH terms Substances Full Text Sources Miscellaneous PubMed Commons 0 comments How to cite this comment

NEJM2015 Full Text: Link to full Text with Trip Pro

16. A randomized trial of icatibant in ACE-inhibitor-induced angioedema.

A randomized trial of icatibant in ACE-inhibitor-induced angioedema. 25629740 2015 01 29 2015 02 04 2015 12 31 1533-4406 372 5 2015 Jan 29 The New England journal of medicine N. Engl. J. Med. A randomized trial of icatibant in ACE-inhibitor-induced angioedema. 418-25 10.1056/NEJMoa1312524 Angioedema induced by treatment with angiotensin-converting-enzyme (ACE) inhibitors accounts for one third of angioedema cases in the emergency room; it is usually manifested in the upper airway and the head (...) and neck region. There is no approved treatment for this potentially life-threatening condition. In this multicenter, double-blind, double-dummy, randomized phase 2 study, we assigned patients who had ACE-inhibitor-induced angioedema of the upper aerodigestive tract to treatment with 30 mg of subcutaneous icatibant, a selective bradykinin B2 receptor antagonist, or to the current off-label standard therapy consisting of intravenous prednisolone (500 mg) plus clemastine (2 mg). The primary efficacy end

NEJM2015

17. A randomized trial of icatibant in ACE-inhibitor-induced angioedema.

A randomized trial of icatibant in ACE-inhibitor-induced angioedema. BACKGROUND: Angioedema induced by treatment with angiotensin-converting-enzyme (ACE) inhibitors accounts for one third of angioedema cases in the emergency room; it is usually manifested in the upper airway and the head and neck region. There is no approved treatment for this potentially life-threatening condition. METHODS: In this multicenter, double-blind, double-dummy, randomized phase 2 study, we assigned patients who had (...) ACE-inhibitor-induced angioedema of the upper aerodigestive tract to treatment with 30 mg of subcutaneous icatibant, a selective bradykinin B2 receptor antagonist, or to the current off-label standard therapy consisting of intravenous prednisolone (500 mg) plus clemastine (2 mg). The primary efficacy end point was the median time to complete resolution of edema. RESULTS: All 27 patients in the per-protocol population had complete resolution of edema. The median time to complete resolution was 8.0

NEJM2015

18. In diabetic patients intolerant of ACE inhibitors and ARBs, what is the best therapy for reducing the risk of diabetic nephropathy?

In diabetic patients intolerant of ACE inhibitors and ARBs, what is the best therapy for reducing the risk of diabetic nephropathy? In diabetic patients intolerant of ACE inhibitors and ARBs, what is the best therapy for reducing the risk of diabetic nephropathy? Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics (...) In diabetic patients intolerant of ACE inhibitors and ARBs, what is the best therapy for reducing the risk of diabetic nephropathy? View/ Open Date 2013-10 Format Metadata Abstract Evidence-Based Answer: Optimizing glucose control and blood pressure in patients with type 1 or type 2 diabetes who are intolerant of angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) may be of benefit in reducing the progression of surrogate measures (ie, microalbuminuria/macroalbuminuria

Evidence Based Practice 2014

19. Systematic review with meta-analysis: ACE inhibitors are associated with a reduction in all-cause mortality versus angiotensin II receptor blockers in patients with diabetes mellitus

Systematic review with meta-analysis: ACE inhibitors are associated with a reduction in all-cause mortality versus angiotensin II receptor blockers in patients with diabetes mellitus ACE inhibitors are associated with a reduction in all-cause mortality versus angiotensin II receptor blockers in patients with diabetes mellitus | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password (...) For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here ACE inhibitors are associated with a reduction in all-cause mortality versus angiotensin II receptor blockers in patients with diabetes mellitus Article Text Therapeutics

Evidence-Based Medicine (Requires free registration)2014

20. Effects of ACE inhibitors on long-term outcome of renal transplant recipients: a randomized controlled trial

Effects of ACE inhibitors on long-term outcome of renal transplant recipients: a randomized controlled trial 23380881 2013 03 19 2013 05 13 2016 11 25 1534-6080 95 6 2013 Mar 27 Transplantation Transplantation Effects of ACE inhibitors on long-term outcome of renal transplant recipients: a randomized controlled trial. 889-95 10.1097/TP.0b013e3182827a43 Available data on the role of renin-angiotensin system blockade in renal transplantation are inconclusive. Herein, we report the long-term (...) results of a randomized controlled trial planned to evaluate the impact of angiotensin-converting enzyme inhibitors (ACE-i) on the cardiovascular outcome of renal transplant recipients (RTRs) receiving calcineurin inhibitors, steroids, and mycophenolate mofetil. Thirty-six RTRs were allocated to receive ACE-i and 34 served as controls. Survival free of a composite endpoint consisting of death, major cardiovascular events, renal graft loss or creatinine doubling, and survival free of each single

EvidenceUpdates2013